Wyeth Pharmaceuticals reveals oestrogens positives

Wyeth Pharmaceuticals has announced that a study into oestrogen treatment of postmenopausal women did not increase incidences of breast cancer.

The company has said that data published in the most recent issue of the Journal of the American Medical Association (Jama) showed that in a sub-study of the Women’s Health Initiative where patients were treated with 0.625mg of conjugated oestrogens, a possible protection against breast cancer in some cases was also shown.

“We know there are many symptomatic menopausal women who are appropriate candidates for oestrogen therapy but are afraid to take it due to concerns about breast cancer risk,” said Dr Ginger Constantine, vice president of Women’s Health Care and Bone Repair at Wyeth Pharmaceuticals.

“It’s important that women talk to their doctor or health care professional about these new results because they show that conjugated oestrogens did not increase the incidence of breast cancer among the menopausal women studied.”

The Jama-published data showed that the possible protection against breast cancer was detected in three groups involved in the study, including those women with no history of benign breast cancer, women with no first-degree relatives affected by the disease and those with a low five-year risk of developing breast cancer according to the Gail Risk Score.

© Adfero Ltd